A prospective study of body fat redistribution, lipid, and glucose parameters in HIV-infected patients initiating combination antiretroviral therapy

HIV Clinical Trials

Volumn 9, Issue 5, 2008, Pages 314-323

  Walmsley, Sharon ^a,b,c,f   Cheung, Angela M ^a,b   Fantus, George ^b,c   Gough, Kevin ^c,d   Smaill, Fiona ^e   Azad, A ^a   Diong, Christina ^a   Raboud, Janet ^a,b  

^a UNIVERSITY HEALTH NETWORK   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

^c MOUNT SINAI HOSPITAL   (Canada)

^d ST MICHAEL'S HOSPITAL   (Canada)

^e MCMASTER UNIVERSITY   (Canada)

^f NONE   (Canada)

Author keywords

Antiretroviral therapy; Body fat; DXA scan; HIV; Lipodystrophy; Metabolic changes

Indexed keywords

ABACAVIR; AMPRENAVIR; ANTILIPEMIC AGENT; DIDANOSINE; EFAVIRENZ; FIBRIC ACID DERIVATIVE; GLUCOSE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INSULIN; LAMIVUDINE; LOPINAVIR; LOW DENSITY LIPOPROTEIN CHOLESTEROL; NELFINAVIR; NEVIRAPINE; PROTEINASE INHIBITOR; RITONAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR; SAQUINAVIR; STAVUDINE; THYMIDINE DERIVATIVE; TRIACYLGLYCEROL; ZIDOVUDINE;

ADULT; ANTHROPOMETRY; ARTICLE; BODY FAT; BODY FAT DISTRIBUTION; BODY MASS; BODY WEIGHT; CHOLESTEROL BLOOD LEVEL; COHORT ANALYSIS; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; DUAL ENERGY X RAY ABSORPTIOMETRY; FEMALE; HIV ASSOCIATED LIPODYSTROPHY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INCIDENCE; INSULIN RESISTANCE; MAJOR CLINICAL STUDY; MALE; PREVALENCE; PRIORITY JOURNAL; PROSPECTIVE STUDY; SIDE EFFECT; TRIACYLGLYCEROL BLOOD LEVEL;

ADIPOSE TISSUE; ADULT; ANTI-RETROVIRAL AGENTS; BLOOD GLUCOSE; BODY COMPOSITION; COHORT STUDIES; DRUG THERAPY, COMBINATION; FEMALE; HIV INFECTIONS; HIV-ASSOCIATED LIPODYSTROPHY SYNDROME; HUMANS; INCIDENCE; LIPIDS; MALE; MIDDLE AGED; PREVALENCE; PROSPECTIVE STUDIES;

EID: 57149118028     PISSN: 15284336     EISSN: None     Source Type: Journal    
DOI: 10.1310/hct0905-314     Document Type: Article

References (55)

1. Palella FJ, Delaney KM, Moorman AC, et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. N Engl J Med. 1998; 338:853-860.
2. Hogg RS, O'Shaughnessy MV, Gataric N, et al. Decline in deaths from AIDS due to new antiretrovirals. Lancet. 1997;349:1294.
3. Wanke C. Epidemiological and clinical aspects of the metabolic complications of HIV infection. The fat redistribution syndrome. AIDS. 1999;13:1287-1293.
4. Roth VR, Kravcik S, Angel JB. Development of cervical fat pads following therapy with HIV type I protease inhibitors. Clin Infect Dis. 1998;27:65-67.
5. Carr A, Samaras K, Burton S et al. A syndrome of peripheral lipodystrophy, hyperlipidaemia and insulin resistance in patients receiving HIV protease inhibitors. AIDS. 1998;12:F51-F56.
6. Carr A, Samara K, Thorisdottir A, et al. Diagnosis, prediction, and natural course of HIV-1 protease-inhibitor associated lipodystrophy, hyperlipidaemia, and diabetes mellitus: A cohort study. Lancet. 1999;353;2093-2099.
7. Saint-Marc T, Partisani M, Poizot-Martin I, et al. A syndrome of peripheral fat wasting inpatients receiving long-term nucleoside analogue therapy. AIDS. 1999;13:1659-1667.
8. Bogner JR, Vielhauer V, Beckmann RA, Michl G, et al. Stavudine versus zidovudine and the development of lipodystrophy. J Acquir Immune Defic Syndr. 2000;27:237-244.
9. Shlay JC, Vinsegarwala F, Bartsch G, Wand J, et al. Body composition and metabolic changes in antiretroviral-naïve patients randomized to Didanosine and Stavudine vs. Abacavir and Lamivudine. J Acquir Immune Defic Syndr. 2005; 38:147-155.
10. Carr A, Miller J, Law M, Cooper DA. A syndrome of lipoatrophy, lactic acidaemia and liver dysfunction associated with HIV nucleoside analogue therapy: Contribution to protease inhibitor-related lipodystrophy syndrome. AIDS. 2000;14(3):F25-32.
11. Brinkman K, Smeitink H, Rominjn J, Reiss P. Mitochondrial toxicity induced by nucleoside-analogue reverse transcriptase inhibitors is a key factor in the pathogenesis of antiretroviral therapy related lipodystrophy. Lancet. 1999; 354:1112-1115.
12. Saghayam S, Kumarasamy N, Cecelia AJ, et al. Weight and body shape changes in a treatment-naïve population after 6 months of Nevirapine-based generic highly active antiretroviral therapy in South India. Clin Infect Dis. 2007;44:295-300.
13. Haubrich R, Riddler S, DiRienzo G, Komarow L, et al. Metabolic outcomes of ACTG 5142: A prospective, randomized, phase III trial of NRTI-, PI-, and NNRTI-sparing regimens for initial treatment of HIV-1 infection. Presented at the 14th Conference on Retroviruses and Opportunistic Infections; February 2007; Los Angeles, CA.
14. Safrin S, Grunfeld. Fat distribution and metabolic changes in patients with HIV infection. AIDS. 1999;13:2493-2505.
15. Brown TT, Chu H, Wang Z, Palella FJ, Kingsley L, et al. Longitudinal increases in waist circumference are associated with HIV-serostatus, independent of antiretroviral therapy. AIDS. 2007;21:1731-1738.
16. Visnegarwala F, Shlay JC, Vaughn B, Gibert CL, et al. Effects of HIV infection on body composition changes among men of different racial/ ethnic origins. HIV Clin Trials. 2007;8(3):145-154.
17. Gervasoni C, Ridolfo AL, Trifiro G, et al. Redistribution of body fat in HIV-infected women undergoing combined antiretroviral therapy. AIDS. 1999;13:465-471.
18. Tsiodras S, Mantzoros C, Hammer S, Samore M. Effects of protease inhibitors on hyperglycemia, hyperlipidemia and lipodystroply. A 5-year cohort study. Arch Intern Med. 2000;160(13):2050-2056.
19. Tien PC, Barron Y, Justman JE, Hyman C, et al. Antiretroviral therapies associated with lipoatrophy in HIV-infected women. AIDS Patient Care STDS. 2007;21(5):297-305.
20. Currier J, Scherzer R, Bacchetti P, Heymsfield S, et al. Regional adipose tissue and lipid and lipoprotein levels in HIV-infected women. J Acquir Immune Defic Syndr. 2008; 48(1):35-43.
21. Gharakhanian S. The HIV associated lipodystrophy syndrome: Research, results yet more questions. AIDS. 2001; 15:271-273
22. Lee E, Walmsley SL, Fantus G. New onset diabetes mellitus associated with protease inhibitor therapy in an HIV-infected patient: Case report and review. Can Med Assoc J. 1999;161:161-164.
23. Heath KV, Hogg RS, Chan KJ, et al. Lipodystrophy-associated morphological, cholesterol and triglyceride abnormalities in a population-based HIV/AIDS treatment database. AIDS. 2001;15:231-239.
24. Fontas E, van Leth F, Sabin CA, Friis-Moller N, Rickenback M, et al. Lipid profiles in HIV-infected patients receiving combination antiretroviral therapy: Are different antiretroviral drugs associated with different lipid profiles? J Infect Dis. 2004;189:1056-1074.
25. Collins E, Wagner C, Walmsley S. Psychosocial impact of the lipodystrophy syndrome. AIDS Reader. 2000;10:546-550.
26. Duran S, Savész M, Spire B, et al. Failure to maintain longterm adherence to highly active antiretroviral therapy: The role of lipodystrophy. AIDS. 2001;15:2441-2444.
27. Blanch J, Rousaud A, Martinez E, De Lazzari E, et al. Factors associated with severe impact of lipodystrophy on the quality of life of patients infected with HIV-1. Clin Infect Dis. 2004;38:1464-1470.
28. Martin A, Smith DE, Carr A, et al. Reversibility of lipoatrophy in HIV-infected patients 2 years after switching from a thymidine analogue to abacavir: The MITOX Extension Study. AIDS. 2004;18:1029-1036.
29. Moyle GJ, Baldwin C, Langroudi B, et al. A 48-week, randomized, open-label comparison of three abacavir-based substitution approaches in the management of dyslipidemia and peripheral lipoatrophy. J Acquir Immune Defic Syndr. 2003;33:22-28.
30. Falutz J, Allas S, Blot K, Potvin D, Kotler D, et al. Metabolic effects of growth hormone-releasing factor in patients with HIV. N Engl J Med. 2007;357(23):2359-2370.
31. Carr A, Workman C, Carey D, Rogers G, et al. No effect of rosiglitazone for treatment of HIV-1 lipoatrophy: Randomised, double-blind, placebo-controlled trial. Lancet. 2004;363(9407):429-438.
32. Cavalcanti R, Raboud J, Shen S, Kain, KC, Cheung A, Walmsley S. A randomized, placebo-controlled trial of rosiglitazone for HIV-related lipodystrophy. J Infect Dis. 2007; 195(12):1754-1761.
33. Grinspoon S, Carr A. Cardiovascular risk and body-fat abnormalities in HIV-infected adults. N Engl J Med. 2005; 352:48-62.
34. DAD Study Group, Friis-Moller N, Reiss P, Sabin CA, et al. Class of antiretroviral drugs and the risk of myocardial infarction. N Engl J Med. 2007;356(17):1723-1735.
35. Bozzette S, Ake C, Tam H, Phippard A, et al. Long-term survival and serious cardiovascular events in HIV-infected patients treated with highly active antiretroviral therapy. J Acquir Immune Defic Syndr. 2008;47(3):338-341.
36. Molarius A, Seidell JC. Selection of anthropometric indicators for classification of abdominal fatness - a critical review. Int J Obesity. 1998;22:719-727.
37. Levy JC, Matthews DR, Hermans MP. Correct homeostasis model assessment (HOMA) evaluation uses the computer program. Diabetes Care. 1998;21:2191-2192.
38. Nathan DM, Cleary PA, Backlund JY, et al. Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes. N Engl J Med. 2005;353(25):2643-2653.
39. Mallal SA, John M, Moore CB, et al. Contribution of nucleoside analogue reverse transcriptase inhibitors to subcutaneous fat wasting in patients with HIV infection. AIDS. 2000;14:1309-1316.
40. Lowe SH, Hassink EA, van Eck-Smitt BL, Borleffs JC, et al. Stavudine but not didanosine as part of HAART contributes to peripheral lipoatrophy: A substudy from the Antiretroviral Regimen Evaluation Study (ARES). HIV Clin Trials. 2007;8(5):337-344.
41. Joly V, Flandre P, Meiffredy V, et al. Increased risk of lipoatrophy under stavudine in HIV-1 infected patients: Results of a substudy from a comparative trial. AIDS. 2002; 16:2441-2454.
42. Chene G, Angelini E, Cotte L, Lang J, et al. Role of longterm nucleoside-analogue therapy in lipodystrophy and metabolic disorders in human immunodeficiency virus-infected patients. Clin Infect Dis. 2002;34:649-657.
43. Mallon P, Miller J, Cooper DA, Carr A. Prospective evaluation of the effects of antiretroviral therapy on body composition in HIV-infected men starting therapy. AIDS. 2003; 17:971-979.
44. Shlay JC, Bartsch G, Peng G, Wang J, et al. Long-term body composition and metabolic changes in antiretroviral naïve persons randomized to protease inhibitor - non-nucleoside reverse transcriptase inhibitor, or protease inhibitor plus non-nucleoside reverse transcriptase inhibitor-based strategy. J Acquir Immune Defic Syndr. 2007; 44:506-517.
45. Mulligan K, Parker RA, Komarow L, Grinspoon SK, et al. Mixed patterns of changes in central and peripheral fat following initiation of antiretroviral therapy in a randomized trial. J Acquir Immune Defic Syndr. 2006;41:590-597.
46. Dube MP, Komarow L, Mulligan K, Grinspoon SK, et al. Long-term body fat outcomes in antiretroviral-naïve participants randomized to Nelfinavir or Efavirenz or both plus dual nucleosides. Dual X-ray absorptiometry results from A5005s, a Substudy of Adult Clinical Trials Group 384. J Acquir Immune Defic Syndr. 2007;45(5):508-514.
47. Dube MP, Qian D, Edmonson-Melancon H, Sattler FR, et al. Prospective, intensive study of metabolic changes associated with 48 weeks of amprenavir-based antiretroviral therapy. Clin Infect Dis. 2002;35:475-481
48. Jensen MD, Kanaley JA, Reed JF, Sheedy PF. Measurement of abdominal and visceral fat with computed tomography and dual-energy x-ray absorptiometry. Am J Clin Nutr. 1995;61:274-278.
49. Bonnet E, Delpierre C, Sommet A, Marion-Latard F, et al. Total body composition by DXA of 241 HIV-negative men and 162 HIV-infected men: Proposal of reference values for defining lipodystrophy. J Clin Densitom. 2005;8(3):287-292.
50. Salamone LM, Fuerst T, Visser M, et al. Measurement of fat mass using DEXA: A validation study in elderly adults. J Appl Physiol. 2000;89:345-352.
51. Cavalcanti RB, Cheung AM, Raboud J, Walmsley S. Reproducibility of DXA estimations of body fat in HIV lipodystrophy. J Clin Dens. 2005;8(3):293-297.
52. Palella FJ, Cole SR, Chmiel JS, Riddler SA, et al. Anthropometrics and examiner-reported body habitus abnormalities in the multi-center AIDS cohort study. Clin Infect Dis. 2004;38:903-907.
53. Martinez E, Mocroft A, Garcia-Viejo MA, et al. Risk of lipodystrophy in HIV-1-infected patients treated with protease inhibitors: A prospective cohort study. Lancet. 2001; 357:592-598.
54. Saag MS, Cahn P, Raffi F, et al. Efficacy and safety of emtricitabine vs stavudine in combination therapy in anti-retroviral-naïve patients: A randomized trial. JAMA. 2004; 292(2):266-268.
55. Pozinak AL, Gallany JE, De Jesus E, Arribas JR, Gazzard B, et al. Tenofovir disoproxil fumarate, emtricitabine, and efavirenz versus fixed-dose zidovudine/lamivudine and efavirens in antiretroviral-naïve patients. Virologic, immunologic, and morphologic changes - a 96-week analysis. J Acquir Immune Defic Syndr. 2006;43:535-540.